Sugi Predict

Sugi Predict / Compounds / SCHEMBL2371070

SCHEMBL2371070

SCHEMBL2371070

CN(C)c1ccc(P(C(C)(C)C)C(C)(C)C)cc1.Cl[Pd]Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 11/20 0.44
▸ TSHR P16473 6/20 0.44
▸ ALOX15 P16050 4/20 0.44
▸ HSD17B10 Q99714 4/20 0.44
▸ SLC2A1 P11166 1/20 0.38
▸ MAPK1 P28482 5/20 0.37
▸ TDP1 Q9NUW8 4/20 0.37
▸ CYP3A4 P08684 3/20 0.37
▸ TP53 P04637 2/20 0.37
▸ HPGD P15428 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ MAPT P10636 3/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ CYP2A6 P11509 1/20 0.33
▸ CYP2A13 Q16696 1/20 0.33
▸ HBB P68871 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10114 1.00 ALDH1A1 (0.44) ALDH1A1TSHRALOX15HSD17B10SLC2A1
SCHEMBL616862 0.92 ALDH1A1 (0.52) ALDH1A1TSHRALOX15HSD17B10SLC2A1
SCHEMBL27892489 0.90 ALDH1A1 (0.46) ALDH1A1TSHRALOX15HSD17B10SLC2A1
Dimethylformamide SCHEMBL28332387 0.90 CYP2A6 (0.39) ALDH1A1TSHRALOX15HSD17B10SLC2A1
SCHEMBL29789670 0.90 ALDH1A1 (0.50) ALDH1A1TSHRALOX15HSD17B10SLC2A1
Hydrochloric Acid SCHEMBL30670337 0.90 ALDH1A1 (0.50) ALDH1A1TSHRALOX15HSD17B10SLC2A1
Hydrochloric Acid SCHEMBL27243769 0.90 ALDH1A1 (0.50) ALDH1A1TSHRALOX15HSD17B10SLC2A1
Hydrochloric Acid SCHEMBL28840014 0.90 ALDH1A1 (0.50) ALDH1A1TSHRALOX15HSD17B10SLC2A1
SCHEMBL29482181 0.90 ALDH1A1 (0.50) ALDH1A1TSHRALOX15HSD17B10SLC2A1
SCHEMBL27822750 0.90 ALDH1A1 (0.50) ALDH1A1TSHRALOX15HSD17B10SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119591541-A Synthesis method of propidium bromide 西安市儿童医院 2025-03-11 — — CN claimed
CN-118047802-A Azaspiro compounds, intermediates thereof and preparation method thereof 常州恒邦药业有限公司 2024-05-17 — — CN claimed
CN-114671745-B Green method for synthesizing biaryl structure-containing compound through Suzuki coupling reaction 江苏和成新材料有限公司 2024-04-05 — — CN claimed
CN-114671744-B Green method for synthesizing biaryl structure-containing compound through Suzuki coupling reaction 江苏和成新材料有限公司 2024-04-05 — — CN claimed
CN-122010941-A Organic condensed ring compound and organic electroluminescent device prepared from same 湖北尚赛光电材料有限公司 2026-05-12 — — CN disclosed
US-20250320194-A1 PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF FUSED PYRIDINE RING DERIVATIVE AND PREPARATION METHOD THEREFOR JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) 2025-10-16 — — US disclosed
CN-119638720-A Heterocyclic compound and organic electroluminescent element comprising same 海宁奕诺炜特科技有限公司 2025-03-18 — — CN disclosed
CN-119591541-A Synthesis method of propidium bromide 西安市儿童医院 2025-03-11 — — CN disclosed
WO-2025038395-A1 BENZOPYRIDINONES AND BENZOPYRIMIDINONES AS PI3K INHIBITORS ONKURE, INC. (US) 2025-02-20 — — WO disclosed
CN-112513050-B Heterocyclic compounds which inhibit SHP2 activity 大鹏药品工业株式会社 2024-12-20 — — CN disclosed
CN-118878509-A Dibenzoheterocycle-containing compound, organic electroluminescent device and display device 阜阳欣奕华新材料科技股份有限公司 2024-11-01 — — CN disclosed
WO-2024147703-A1 SHP2 INHIBITOR AND USES THEREOF 주식회사 카나프테라퓨틱스 2024-07-11 — — WO disclosed
EP-2547686-A1 AMINO -DIHYDROOXAZINE AND AMINO - DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA - SECRETASE MODULATORS AND THEIR MEDICAL USE Amgen Inc. (US) 2013-01-23 — — EP disclosed
WO-2013006634-A2 PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-10 — — WO disclosed
WO-2012071279-A1 SPIRO-AMINO-IMIDAZOLONE AND SPIRO-AMINO-DIHYDRO-PYRIMIDINONE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2012-05-31 — — WO disclosed
EP-2370424-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2011-10-05 — — EP disclosed
WO-2011115928-A1 AMINO -DIHYDROOXAZINE AND AMINO - DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA - SECRETASE MODULATORS AND THEIR MEDICAL USE AMGEN INC. (US) 2011-09-22 — — WO disclosed
EP-2364306-A1 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors Amgen Inc. (US) 2011-09-14 — — EP disclosed
WO-2010057126-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2010-05-20 — — WO disclosed
WO-2010054398-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320194-A1 PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF FUSED PYRIDINE RING DERIVATIVE AND PREPARATION METHOD THEREFOR GOT1, CS, FARS2 ALDH1A1 1575/4885TSHR 2628/4885ALOX15 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.